Analysts Expect Evoke Pharma Inc (NASDAQ:EVOK) to Post -$0.12 Earnings Per Share

Wall Street analysts expect Evoke Pharma Inc (NASDAQ:EVOK) to report earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evoke Pharma’s earnings. Evoke Pharma reported earnings of ($0.14) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 14.3%. The firm is expected to report its next earnings results on Thursday, August 15th.

On average, analysts expect that Evoke Pharma will report full year earnings of ($0.35) per share for the current financial year. For the next fiscal year, analysts forecast that the company will post earnings of ($0.19) per share. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03.

EVOK has been the topic of several research reports. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a research report on Tuesday. HC Wainwright reissued a “hold” rating on shares of Evoke Pharma in a research report on Friday, August 9th. Finally, ValuEngine raised Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Evoke Pharma during the first quarter worth about $118,000. Marshall Wace LLP purchased a new stake in shares of Evoke Pharma during the first quarter worth about $139,000. Citadel Advisors LLC purchased a new stake in shares of Evoke Pharma during the second quarter worth about $37,000. Finally, BlackRock Inc. increased its position in shares of Evoke Pharma by 5.5% during the fourth quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock worth $207,000 after acquiring an additional 4,392 shares during the last quarter. 7.40% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:EVOK traded up $0.02 during mid-day trading on Thursday, hitting $0.86. The company had a trading volume of 135,076 shares, compared to its average volume of 712,145. The business has a fifty day simple moving average of $0.89. Evoke Pharma has a 1 year low of $0.50 and a 1 year high of $3.40. The company has a market capitalization of $19.31 million, a price-to-earnings ratio of -1.87 and a beta of 1.62.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Further Reading: What is the yield curve?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.